AnaptysBio, Inc. (ANAB) Bundle
Understanding AnaptysBio, Inc. (ANAB) Revenue Streams
Understanding AnaptysBio’s Revenue Streams
The primary revenue sources for the company include collaboration revenue, which is derived from milestone payments, royalty payments, and amortization of upfront license payments from partners.
Breakdown of Primary Revenue Sources
- Collaboration Revenue: Total collaboration revenue for the nine months ended September 30, 2024, was $48.2 million, compared to $8.2 million for the same period in 2023.
- Royalty Revenue: For the nine months ended September 30, 2024, royalty revenue was $33.2 million, an increase from $8.2 million in 2023.
- Interest Income: Interest income amounted to $14.5 million for the nine months ended September 30, 2024, compared to $14.0 million during the same period in 2023.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for collaboration revenue reflects a significant increase of 487% from 2023 to 2024.
Contribution of Different Business Segments to Overall Revenue
| Revenue Source | Q3 2024 ($ in millions) | Q3 2023 ($ in millions) | Change (%) |
|---|---|---|---|
| Collaboration Revenue | 30.0 | 3.3 | 809% |
| Royalty Revenue | 15.0 | 3.3 | 355% |
| Interest Income | 5.3 | 4.9 | 8.16% |
Analysis of Significant Changes in Revenue Streams
During the nine months ended September 30, 2024, the company recognized a first sales milestone of $15.0 million when Jemperli annual sales exceeded $250 million. This was a new revenue category recognized in 2024, as no sales milestones were recognized in 2023.
The royalty revenue for the nine months ended September 30, 2024, included $30.1 million related to Jemperli and $3.1 million related to Zejula, marking a substantial growth compared to the previous year.
The company has not generated any revenue from product sales, and all revenue recognized is non-cash revenue pursuant to the Royalty Monetization Agreements.
A Deep Dive into AnaptysBio, Inc. (ANAB) Profitability
A Deep Dive into AnaptysBio, Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was approximately 61.9%, compared to 40.7% for the same period in 2023.
Operating Profit Margin: The operating profit margin for the nine months ended September 30, 2024, was -69.0%, down from -93.7% in the corresponding period of 2023.
Net Profit Margin: The net profit margin for the nine months ended September 30, 2024, stood at -256.7%, in comparison to -254.2% for the same period in 2023.
Trends in Profitability Over Time
Over the last several quarters, the company's profitability has shown fluctuations. The loss from operations for the nine months ended September 30, 2024, was $105.3 million, an improvement from $122.3 million for the same period in 2023. However, net losses have increased slightly from $121.4 million in 2023 to $123.4 million in 2024, indicating a challenging market environment.
Comparison of Profitability Ratios with Industry Averages
In comparison to the biotechnology industry averages, which typically show an average net profit margin of around -50% during the early stages of product development, AnaptysBio's net margin of -256.7% indicates significant operational challenges relative to its peers.
| Metric | AnaptysBio 2024 | AnaptysBio 2023 | Industry Average |
|---|---|---|---|
| Gross Profit Margin | 61.9% | 40.7% | 50% |
| Operating Profit Margin | -69.0% | -93.7% | -50% |
| Net Profit Margin | -256.7% | -254.2% | -50% |
Analysis of Operational Efficiency
The operational efficiency of AnaptysBio has been impacted by rising costs in research and development. For the nine months ended September 30, 2024, research and development expenses were $121.3 million, compared to $98.8 million in 2023. This represents a year-over-year increase of approximately 22.7%.
General and administrative expenses also saw an increase, totaling $32.2 million for the nine months ended September 30, 2024, compared to $31.7 million in the same period of 2023. This increase in operational costs has contributed to the overall decline in profitability metrics.
In summary, AnaptysBio's profitability metrics reveal a mixed picture with improvements in gross profit margin but ongoing challenges in net and operating margins compared to industry averages.
Debt vs. Equity: How AnaptysBio, Inc. (ANAB) Finances Its Growth
Debt vs. Equity: How AnaptysBio Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, AnaptysBio reported total liabilities of $409.1 million, comprised of current liabilities of $43.9 million and long-term liabilities of $365.2 million. The long-term liabilities include a significant component related to the sale of future royalties, which amounted to $350.6 million.
Debt-to-Equity Ratio
The debt-to-equity ratio for AnaptysBio as of September 30, 2024, stood at approximately 4.85, calculated using total liabilities of $409.1 million and total stockholders' equity of $84.4 million. This ratio is notably higher than the industry average, which typically ranges from 1.0 to 2.0 for biotech companies, indicating a more aggressive use of debt financing compared to peers.
Recent Debt Issuances and Credit Ratings
In August 2024, the company issued 2,750,498 shares of common stock at an offering price of $36.50 per share, generating net proceeds of approximately $93.9 million. Additionally, AnaptysBio has been utilizing royalty monetization agreements, which have been structured as liabilities rather than traditional debt, contributing to its current debt levels.
As of the latest reports, AnaptysBio has not received a formal credit rating from major credit rating agencies, as it primarily operates within the biotech sector and relies on equity financing and partnerships for funding its operations.
Balancing Debt Financing and Equity Funding
AnaptysBio has strategically balanced debt financing and equity funding to support its growth. The company has raised approximately $738.6 million through the sale of equity securities since its inception. In addition, it has entered into agreements to receive milestone and contingent payments from collaborations, enhancing its funding flexibility without increasing debt levels significantly.
| Financial Metric | Value |
|---|---|
| Total Liabilities | $409.1 million |
| Current Liabilities | $43.9 million |
| Long-term Liabilities | $365.2 million |
| Debt-to-Equity Ratio | 4.85 |
| Common Stock Issued (Aug 2024) | 2,750,498 shares |
| Offering Price per Share | $36.50 |
| Net Proceeds from Offering | $93.9 million |
| Equity Raised Since Inception | $738.6 million |
Assessing AnaptysBio, Inc. (ANAB) Liquidity
Assessing AnaptysBio, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as:
Current Assets: $448.7 million
Current Liabilities: $43.9 million
Thus, the current ratio is approximately 10.21, indicating strong liquidity.
Quick Ratio: The quick ratio, which excludes inventory, is calculated using:
Current Assets (excluding inventory): $448.7 million
Current Liabilities: $43.9 million
Therefore, the quick ratio is also approximately 10.21.
Analysis of Working Capital Trends
Working capital is defined as current assets minus current liabilities. As of September 30, 2024:
Working Capital: $448.7 million - $43.9 million = $404.8 million
This represents an increase from December 31, 2023, when working capital was $369.4 million.
Cash Flow Statements Overview
The following table summarizes cash flows for the nine months ended September 30, 2024, and 2023:
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash (used in) provided by operating activities | $(68,665) | $(86,451) |
| Net cash provided by investing activities | $124,794 | $95,576 |
| Net cash provided by financing activities | $99,487 | $(54,138) |
| Net increase (decrease) in cash and cash equivalents | $155,616 | $(45,013) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company holds $458.0 million in cash, cash equivalents, and investments, up from $417.9 million as of December 31, 2023 .
Operating activities for the nine months ended September 30, 2024, showed a net cash outflow of $(68.7 million), primarily due to a net loss of $(123.4 million) .
In terms of financing, the company generated $99.5 million in net cash, which includes proceeds from public offerings and the sale of future royalties .
Overall, the liquidity position remains strong, supported by significant cash reserves and positive cash flows from investing and financing activities. However, the ongoing net cash used in operating activities indicates a need for careful monitoring of expenses and potential future financing requirements.
Is AnaptysBio, Inc. (ANAB) Overvalued or Undervalued?
Valuation Analysis
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the company reported a net loss of $123.4 million for the nine months ended September 30, 2024, leading to a basic and diluted net loss per share of $4.46 . Given that the company is currently not profitable, the P/E ratio cannot be calculated as there are no earnings to evaluate against the stock price.
Price-to-Book (P/B) Ratio
The book value per share as of September 30, 2024, was calculated from total stockholders' equity of $84.37 million and 30.43 million shares outstanding, resulting in a book value per share of approximately $2.77 . If the stock price is currently trading at $36.50, the P/B ratio would be 13.16.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value is calculated as market capitalization plus total debt minus cash. As of September 30, 2024, the company had $458 million in cash and cash equivalents . The total liabilities were $409.05 million . Assuming the stock price is $36.50, the market capitalization would be approximately $1.11 billion. Thus, the enterprise value is $1.11 billion + $409.05 million - $458 million = $1.06 billion. With EBITDA for the nine months ended September 30, 2024, being $(105.28 million) , the EV/EBITDA ratio cannot be calculated as EBITDA is negative.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated with a high of $36.50 and a low of approximately $18.00 . This represents a significant increase over the year, reflecting a recovery trend in the biotechnology sector.
Dividend Yield and Payout Ratios
The company does not currently pay a dividend, thus the dividend yield is 0% . As there are no dividends, the payout ratio is also not applicable.
Analyst Consensus on Stock Valuation
Analyst consensus indicates a rating of Hold based on the current financial performance and market conditions. Some analysts express concerns about the company's ability to achieve profitability in the near term, while others see potential based on collaboration agreements and product pipeline .
| Metric | Value |
|---|---|
| Net Loss (9 Months Ended Sept 30, 2024) | $123.4 million |
| Net Loss Per Share (Basic and Diluted) | $4.46 |
| Book Value Per Share | $2.77 |
| P/B Ratio | 13.16 |
| Enterprise Value | $1.06 billion |
| EBITDA (9 Months Ended Sept 30, 2024) | $(105.28 million) |
| Stock Price (Latest) | $36.50 |
| Stock Price High (Last 12 Months) | $36.50 |
| Stock Price Low (Last 12 Months) | $18.00 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing AnaptysBio, Inc. (ANAB)
Key Risks Facing AnaptysBio, Inc. (ANAB)
Overview of Internal and External Risks:
- As of September 30, 2024, the company reported an accumulated deficit of $737.5 million.
- The total liabilities were $409.1 million.
- Cash, cash equivalents, and investments totaled $458.0 million.
- Net loss for the nine months ended September 30, 2024, was $123.4 million.
- The company relies heavily on collaborations, with $48.2 million in collaboration revenue reported for the nine months ended September 30, 2024.
Discussion of Operational, Financial, or Strategic Risks:
- For the nine months ended September 30, 2024, operating expenses were $153.4 million, up from $130.4 million in the same period of 2023.
- Research and development expenses increased to $121.3 million in 2024 from $98.8 million in 2023.
- Non-cash interest expense for the sale of future royalties was $32.7 million for the nine months ended September 30, 2024.
- The company reported a loss from operations of $105.3 million for the nine months ended September 30, 2024.
Mitigation Strategies or Plans:
- The company has entered into royalty monetization agreements, including a $35.0 million agreement related to GSK's Zejula.
- As of September 30, 2024, the company had a sales agreement to offer and sell shares of common stock for up to $100.0 million.
- Future milestone payments and contingent payments are anticipated from collaborations, although these are dependent on various factors.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Accumulated Deficit | Significant operational losses affecting financial stability | $737.5 million |
| Total Liabilities | High level of liabilities relative to assets | $409.1 million |
| Collaboration Revenue | Dependency on collaborators for revenue generation | $48.2 million |
| Operating Expenses | Rising costs in R&D and general operations | $153.4 million |
| Non-cash Interest Expense | Financial burden from royalty agreements | $32.7 million |
Future Growth Prospects for AnaptysBio, Inc. (ANAB)
Future Growth Prospects for AnaptysBio, Inc.
Key Growth Drivers
- Product Innovations: The company is advancing multiple product candidates, including Rosnilimab, ANB032, ANB033, and ANB101. Research and development expenses increased to $42.2 million in Q3 2024 from $30.9 million in Q3 2023.
- Market Expansions: The company has recognized collaboration revenues of $30.0 million in Q3 2024, up from $3.3 million in Q3 2023, indicating significant market traction.
- Acquisitions: The company has entered into various partnership agreements which may lead to future acquisition opportunities.
Future Revenue Growth Projections
Revenue projections for the next fiscal year suggest substantial growth based on the ongoing monetization agreements and anticipated product launches. The collaboration revenue for the nine months ended September 30, 2024, was $48.2 million, compared to $8.2 million for the same period in 2023.
| Year | Revenue ($ millions) | Growth Rate (%) |
|---|---|---|
| 2023 | 8.2 | N/A |
| 2024 (Projected) | 48.2 | 487% |
Strategic Initiatives and Partnerships
The company has established several key partnerships, including a notable agreement with GSK. Under the GSK Royalty Monetization Agreement, the company received $50.0 million for future royalties, enhancing its liquidity and funding potential growth initiatives.
Competitive Advantages
- Strong Intellectual Property: The company holds robust patents that protect its innovations, providing a competitive edge in the biotech space.
- Established Collaborations: Partnerships with major pharmaceutical companies enhance credibility and open additional revenue streams.
- Financial Position: As of September 30, 2024, the company reported cash and cash equivalents totaling $191.6 million, positioning it well for future investments in R&D and market expansion.
Recent Financial Highlights
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss | ($32.9 million) | ($37.3 million) |
| Operating Expenses | $52.8 million | $41.1 million |
| Research and Development Expenses | $42.2 million | $30.9 million |
These financial metrics reflect the company's commitment to investing in growth while managing its operational expenses effectively.
AnaptysBio, Inc. (ANAB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- AnaptysBio, Inc. (ANAB) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of AnaptysBio, Inc. (ANAB)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View AnaptysBio, Inc. (ANAB)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.